TCTMD’s Top 10 Most Popular Stories for November 2021
Late-breaking trials from the TCT and AHA meetings took over the list this month, the lone outlier being our COVID-19 Dispatch.
It was a busy month for meetings on TCTMD, where we managed comprehensive coverage of both the TCT and AHA 2021 conferences, as well as some hot line abstracts from PCR London Valves. The only nonmeeting news to break into the Top 10 was our COVID-19 Dispatch.
Interventionalists and surgeons call it a big win for CABG surgery, especially since its advantages were seen so early.
“This is a very infrequent complication, and . . . overall it’s quite mild and not severe,” James Hermiller Jr told a TCT audience.
The results need confirmation in a larger trial but add to other emerging data supporting an early start for SGLT2 inhibitors.
We update our Dispatch with the top research and health policy news, as well as media highlights, three times per week.
Early dosing and safety data point to minimal side effects and strong LDL effects, but the road ahead is long and cost will be key.
While similar to the RECOVERY trial, AVATAR mandated exercise testing to assure true asymptomatic status, one investigator says.
After 2 years, clinical outcomes were similar, hemodynamics favored TAVI, and paravalvular leak favored surgery.
The investigator-initiated study highlights the advantages of sutures over the plug-based strategy to close after TAVI.
Quicker CABG can lessen the “major headache” of patients waiting and degrading in-hospital.
An eagerly awaited review is spurring calls to stop bickering and agree on the “facts” about left main revascularization.